标签归档：sbi

Heptamidine dimethanesulfonate(Synonyms: SBi4211 dimethanesulfonate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Heptamidine dimethanesulfonate (Synonyms: SBi4211 dimethanesulfonate) 纯度: 99.72%

Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) 是一种强效的，与喷他脒 (HY-B0537) 有关的钙结合蛋白 S100B 的抑制剂 (Kd=6.9 μM)，选择性地杀死表达 S100B 的黑素瘤细胞。Heptamidine dimethanesulfonate 是研究强直性肌营养不良 (DM) 的有效工具。

Heptamidine dimethanesulfonate(Synonyms: SBi4211 dimethanesulfonate)

Heptamidine dimethanesulfonate Chemical Structure

CAS No. : 161374-55-6

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3700 In-stock
5 mg ￥3000 In-stock
10 mg ￥4800 In-stock
50 mg ￥13000 In-stock
100 mg 询价

* Please select Quantity before adding items.

Heptamidine dimethanesulfonate 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Anti-Cancer Compound Library

生物活性

Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B[1]. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM)[2].

IC50 & Target

Kd: 6.9 μM (calcium-binding protein S100B)[1]
体外研究
(In Vitro)

Heptamidine is a Pentamidine-S100B complex, two molecules of pentamidine bind per monomer of S100B, which performs to be an inhibitor for S100B[1].
Heptamidine (20 μM) does not decrease CUG levels significantly when compares to Propamidine and Pentamidine, and exhibits cytotoxic at concentrations above 17.5 μM in HeLa cells expressing 960 CUG repeats[2].
Heptamidine rescues mis-splicing of minigene reporters in a HeLa cell DM1 model with an EC50 value of 15 μM[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Heptamidine (intraperitoneal injection; 20 or 30 mg/kg; 7 days) causes a dose-dependent reduction of exon 7a inclusion in HSALR mice, returning to wild type levels (6±1%) when at 20 mg/kg dose, the myotonia is reduced from grade 3 to grade 1 (occasional myotonic discharge) or grade 0 at both 20 or 30 mg/kg[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Homozygous HSALR transgenic mice in line 20b (FVB inbred background) with a Myotonic dystrophy (DM) mouse model[2]
Dosage: 20 or 30 mg/kg
Administration: Intraperitoneal injection; 7 days; once daily
Result: Reversed splicing defects and rescues myotonia in a DM mouse model.

分子量

560.68

Formula

C23H36N4O8S2
CAS 号

161374-55-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 62.5 mg/mL (111.47 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7835 mL 8.9177 mL 17.8355 mL
5 mM 0.3567 mL 1.7835 mL 3.5671 mL
10 mM 0.1784 mL 0.8918 mL 1.7835 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.71 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.71 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.71 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.71 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.71 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.71 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. McKnight LE, et al. Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B. ACS Med Chem Lett. 2012 Dec 13;3(12):975-979. Epub 2012 Sep 25.

    [2]. Coonrod LA, et al. Reducing levels of toxic RNA with small molecules.ACS Chem Biol. 2013 Nov 15;8(11):2528-37.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SBI-581

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SBI-581 

SBI-581是一种口服有效的选择性的丝氨酸苏氨酸激酶 TAO3 抑制剂，IC50 值为 42 nM。SBI-581 促进 RAB11 阳性囊泡中 TKS5α 的积累。SBI-581 抑制侵袭性伪足形成。SBI-581 在小鼠腹腔注射后的药代动力学较为合理。SBI-581 具有抗肿瘤活性。

SBI-581

SBI-581 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SBI-581 is an orally active and potent selective serine-threonine kinase TAO3 inhibitor, with an IC50 of 42 nM. SBI-581 promotes TKS5α accumulation at RAB11-positive vesicles. SBI-581 inhibits invadopodia formation. SBI-581 shows reasonable pharmacokinetics in mice using IP injection. SBI-581 shows antitumor activity[1].

IC50 & Target

IC50: 42 nM (TAO3), 237 nM (MEKK3)[1]
体外研究
(In Vitro)

SBI-581 shows moderate selectivity (> 5-10x) against the majority of a broad panel of kinases[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

SBI-581 (10 mg/kg, IP, once) displays reasonable pharmacokinetics (t1/2=1.5 hr; AUC= 1202 hr*ng/mL; Cmax= ~2 μM)[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

383.44

Formula

C24H21N3O2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Iizuka S, et al. Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth. Cancer Res. 2021 Mar 15;81(6):1472-1485.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SBI-0206965

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SBI-0206965  纯度: 99.39%

SBI-0206965 是一种强效, 选择性和细胞渗透性自噬激酶 ULK1 抑制剂, 抑制 ULK1 和 ULK2 激酶活性, IC50 值分别为 108 nM 和 711 nM。

SBI-0206965

SBI-0206965 Chemical Structure

CAS No. : 1884220-36-3

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1453 In-stock
5 mg ￥1350 In-stock
10 mg ￥2150 In-stock
50 mg ￥6550 In-stock
100 mg ￥11000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

SBI-0206965 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Targeted Diversity Library

生物活性

SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2[1].

IC50 & Target

ULK1

108 nM (IC50)

ULK2

711 nM (IC50)

体外研究
(In Vitro)

SBI-0206965 (5-20 μM; 24 hours) induces apoptosis of A498 and ACHN cells during starvation[1].
SBI-0206965 (5-20 μM; 24 hours) attenuates the phosphorylation of Ser108 of the AMPK β1 subunit and increases the levels of cleaved Caspase 8 and PARP, markers of apoptosis[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line: A498 and ACHN cells (starvation medium (EBSS) treatment)
Concentration: 5, 10 ,20 μM
Incubation Time: 24 hours
Result: Induced significant levels of apoptosis.

Western Blot Analysis[1]

Cell Line: A498 and ACHN cells (EBSS treatment)
Concentration: 5, 10, 20 μM
Incubation Time: 24 hours
Result: Attenuated the phosphorylation of Ser108 of the AMPK β1 subunit and increased the levels of cleaved Caspase 8 and PARP, markers of apoptosis. Autophagy was evaluated by analysis of LC3B and p62.

体内研究
(In Vivo)

SBI-0206965 (50 mg/kg; i.p.; once every 3 days for 37 days) inhibites tumour growth and induces apoptosis in A498 xenograft tumours[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-week-old male BALB/c nude mice (A498 xenograft tumours)[1]
Dosage: 50 mg/kg
Administration: Intraperitoneal injection; once every three days for 37 days
Result: Significantly suppressed tumour growth.

分子量

489.32

Formula

C21H21BrN4O5
CAS 号

1884220-36-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (204.37 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0437 mL 10.2183 mL 20.4365 mL
5 mM 0.4087 mL 2.0437 mL 4.0873 mL
10 mM 0.2044 mL 1.0218 mL 2.0437 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.11 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.11 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Lu J, et al. Overexpression of ULK1 Represents a Potential Diagnostic Marker for Clear Cell RenalCarcinoma and the Antitumor Effects of SBI-0206965. EBioMedicine. 2018 Aug;34:85-93.

    [2]. Egan DF, et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Mol Cell. 2015 Jul 16;59(2):285-97.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SBI-0640756(Synonyms: SBI-756)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SBI-0640756 (Synonyms: SBI-756) 纯度: 98.52%

SBI-0640756 (SBI-756) 是一种 eIF4G1 抑制剂，能够破坏 eIF4F 复合体。

SBI-0640756(Synonyms: SBI-756)

SBI-0640756 Chemical Structure

CAS No. : 1821280-29-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1603 In-stock
2 mg ￥1100 In-stock
5 mg ￥1800 In-stock
10 mg ￥3000 In-stock
25 mg ￥6000 In-stock
50 mg ￥9900 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

SBI-0640756 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library

生物活性

SBI-0640756 (SBI-756) is an inhibitor of eIF4G1 and disrupts the eIF4F complex.

IC50 & Target

eIF4G1[1]
体外研究
(In Vitro)

SBI-0640756 (SBI-756) is a water soluble inhibitor of eIF4G1. SBI-0640756 (SBI-756) (0-1 μM) disrupts eIF4F complex in parent and BRAFi-resistant melanoma. SBI-0640756 (SBI-756) shows inhibitory effect on human melanoma lines, and also suppresses AKT, NF-κB and AKT/mTORC1 activity[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

SBI-0640756 (SBI-756) (0.5 mg/kg, i.p.) delays tumor onset and reduces tumor incidence by 50% in NrasQ61K/Ink4a–/– genetic model. SBI-0640756 (SBI-756) (1 mg/kg, 2 times per week, i.p.) in combination with BRAF inhibitor potently suppresses growth of established tumors and does not resume tumor growth in immunodeficient mice bearing A375 tumors[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

404.82

Formula

C23H14ClFN2O2
CAS 号

1821280-29-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 26 mg/mL (64.23 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4702 mL 12.3512 mL 24.7023 mL
5 mM 0.4940 mL 2.4702 mL 4.9405 mL
10 mM 0.2470 mL 1.2351 mL 2.4702 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Feng Y et al. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Res, 2015 Dec 15, 75(24):5211-8.
Cell Assay
[1]

WM793, Lu1205, WM1346 and WM1366 melanoma cells are seeded at 1500 cells in 50 μL per well in 384-well plates. Cells are allowed to attach overnight. SBI-0640756 (SBI-756) or derivatives analogs are serially diluted 2-fold with media from stock solutions and added to cells. Tests are performed in triplicate, and each microplate included media and DMSO control wells. Cell viability is assessed using ATPlite after 48 or 72 h. Cell growth inhibition is calculated as a percentage of DMSO-treated controls and plotted against the log drug concentration. IC50 values are interpolated from the resulting linear regression curve fit[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Mice[1]
Six-week-old female nu/nu mice are allowed to acclimatize for 1 week. A375 cells (1 × 106, suspended in 200 μL sterile PBS) are injected into subcutaneous flank tissue. When the xenograft size reach ∼250 mm3, mice are sorted into different groups. For PLX4720 and SBI-0640756 (SBI-756) combination experiments, mice are either fed PLX4720-containing chow alone (AIN76A Roden Diet with 417 mg PLX4720/kg) for the control group or PLX4720-containing chow plus an IP injection of 1 mg/kg SBI-0640756 twice a week. For MEKi plus SBI-0640756 (SBI-756) experiments, PD0325901 at 20 mg/kg (formulated in 0.5% hydroxypropyl methylcellulose plus 0.2% Tween-80) is administered by oral gavage twice a week (Monday and Thursday) for the control group, or PD035901 plus IP injection of 1 mg/kg SBI-0640756 (SBI-756) is administered twice a week (Tuesday and Friday)[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Feng Y et al. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Res, 2015 Dec 15, 75(24):5211-8.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Heptamidine(Synonyms: SBi4211)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Heptamidine (Synonyms: SBi4211)

Heptamidine (SBi4211) 是一种强效的 Pentamidine-related 钙结合蛋白 S100B 的抑制剂 (Kd=6.9 μM)，选择性地杀死表达 S100B 的黑素瘤细胞。Heptamidine 是研究强直性肌营养不良 (DM) 的有效工具。

Heptamidine(Synonyms: SBi4211)

Heptamidine Chemical Structure

CAS No. : 94345-47-8

规格 价格 是否有货
5 mg ￥3000 询问价格 & 货期
10 mg ￥4800 询问价格 & 货期
50 mg ￥13000 询问价格 & 货期
100 mg ￥20000 询问价格 & 货期

* Please select Quantity before adding items.

Heptamidine 的其他形式现货产品:

Heptamidine dimethanesulfonate

生物活性

Heptamidine (SBi4211) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B[1]. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM)[2].

IC50 & Target

Kd: 6.9 μM (calcium-binding protein S100B)[1]
体外研究
(In Vitro)

Heptamidine is a Pentamidine-S100B complex, two molecules of pentamidine bind per monomer of S100B, which performs to be an inhibitor for S100B[1].
Heptamidine (20 μM) does not decrease CUG levels significantly when compares to Propamidine and Pentamidine, and exhibits cytotoxic at concentrations above 17.5 μM in HeLa cells expressing 960 CUG repeats[2].
Heptamidine rescues mis-splicing of minigene reporters in a HeLa cell DM1 model with an EC50 value of 15 μM[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Heptamidine (intraperitoneal injection; 20 or 30 mg/kg; 7 days) causes a dose-dependent reduction of exon 7a inclusion in HSALR mice, returning to wild type levels (6±1%) when at 20 mg/kg dose, the myotonia is reduced from grade 3 to grade 1 (occasional myotonic discharge) or grade 0 at both 20 or 30 mg/kg[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Homozygous HSALR transgenic mice in line 20b (FVB inbred background) with a Myotonic dystrophy (DM) mouse model[2]
Dosage: 20 or 30 mg/kg
Administration: Intraperitoneal injection; 7 days; once daily
Result: Reversed splicing defects and rescues myotonia in a DM mouse model.

分子量

368.47

Formula

C21H28N4O2
CAS 号

94345-47-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. McKnight LE, et al. Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B. ACS Med Chem Lett. 2012 Dec 13;3(12):975-979. Epub 2012 Sep 25.

    [2]. Coonrod LA, et al. Reducing levels of toxic RNA with small molecules.ACS Chem Biol. 2013 Nov 15;8(11):2528-37.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务